In primary AML cells, primary B-CLL cells, and in the leukemia cell lines, FK866 enhanced the cytotoxic activity of the HDAC inhibitors in a synergistic manner (Figure 5, 6A–B, S12, S13, S14, S15, and Table S5). This evidence concerns the gene HDAC9 and leukemia.